Table 1.
Patient demographics and operative characteristics.
| Variable | All patients (n=2656) |
|---|---|
| Median Age, years (IQR) | 60 (IQR 51-68) |
| Sex | |
| Female | 940 (35.4%) |
| Male | 1716 (64.6%) |
| Race | |
| African American | 507 (19.1%) |
| Non-African American | 2137 (80.5%) |
| Not specified | 13 (0.5%) |
| Mean BMI (Kg/m2, ± SD) | 29.9 ± 6.7 |
| HTN | 925 (34.8%) |
| DM | 358 (13.5%) |
| CAD | 331 (12.5%) |
| Mean clinical tumor size (cm, ± SD) | 5.6 ± 3.7 |
| Surgery type | |
| Partial | 1555 (58.5%) |
| Radical | 1101 (41.5%) |
| Tumor Histology | |
| Clear Cell | 2202 (82.9%) |
| Non-Clear Cell | 454 (17.1%) |
| Tumor AJCC Stage | |
| Stage I | 1529 (57.6%) |
| Stage II | 201 (7.6%) |
| Stage III | 583 (22.0%) |
| Stage IV | 343 (12.9%) |
| Metastasis (M1) | 466 (17.5%) |
| Nuclear Grade | |
| Low Grade (Grade 1, 2) | 1320 (49.7%) |
| High Grade (Grade 3, 4) | 1246 (49.7%) |
| Unclassified | 90 (3.4%) |
| Baseline eGFR < 60 mL/min/1.73m2 | 923 (34.8%) |
| De novo eGFR < 60 mL/min/1.73m2 | 578 (21.8%) |
| De novo eGFR < 45 mL/min/1.73m2 | 457 (17.2%) |
| De novo eGFR < 30 mL/min/1.73m2 | 196 (7.4%) |
| Median preoperative NLR | 2.50 95% CI: IQR 1.78 - 3.63] |
| NLR ≥ 2.27 | 874 (32.9%) |
| Median preoperative PLR | 125 [IQR 91.40-174.80] |
| PLR ≥ 165 | 480 (18.1%) |
| Median preoperative AST/ALT | 2.65 95% CI: IQR 1.25 - 2.90] |
| AST/ALT ≥ 2.72 | 932 (35.1%) |
| Median length of follow-up (months) | 30 [IQR 10.7-74.8] |
| All-cause deaths (events) | 628 (23.6%) |
| Non-cancer deaths (events) | 293 (11.0%) |
| Cancer-specific deaths (events) | 335 (12.6%) |